{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T10:44:36Z","timestamp":1758192276756,"version":"3.44.0"},"reference-count":54,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T00:00:00Z","timestamp":1758067200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No.81960031"],"award-info":[{"award-number":["No.81960031"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009619","name":"Science and Technology Bureau, Guiyang Municipal Government","doi-asserted-by":"publisher","award":["Grant NO. 20161001021"],"award-info":[{"award-number":["Grant NO. 20161001021"]}],"id":[{"id":"10.13039\/501100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Objective<\/jats:title>\n<jats:p>Acute Myeloid Leukemia (AML) is a heterogeneous disease with limited therapeutic options and poor prognosis for patients. Therefore, the aim of this study was to evaluate the potential value of TRIM6 as a prognostic marker in AML.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods<\/jats:title>\n<jats:p>In this study, the low-expressed gene TRIM6 was obtained by analysis of The Cancer Genome Atlas (TCGA-AML) and Genotype-Tissue Expression (GTEx) databases.The prognostic impact of TRIM6 was analyzed using Kaplan-Meier curves, univariate COX, multivariate COX, and columnar plot models. The signaling pathways associated with TRIM6 were obtained using Gene Set Variation Analysis (GSVA) and Gene Set Enrichment Analysis (GSEA) methods. Infiltrating immune cells associated with TRIM6 expression were analyzed using the \u201cCIBERSORT\u201d method. Mutations in AML patients were characterized using relevant Single Nucleotide Polymorphism (SNP) data. The effect of TRIM6 expression on AML cell progression was further analyzed by qRT-PCR, CCK-8 assay, flow cytometry and Western blot.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>By analyzing TCGA-AML and GTEx data, TRIM6 was found to be under-expressed in AML patients, and Kaplan-Meier curves, one-way and multifactorial Cox regression models suggested that under-expression of TRIM6 had a poor prognosis. In addition, monocyte, M2 macrophage and memory B cell infiltration levels were found to be higher in the TRIM6 low-expression group than in the TRIM6 high-expression group based on the \u201cCIBERSORT\u201d method. Further mutational characterization showed that TRIM6 expression was positively correlated with NPM1 mutations and negatively correlated with mutations in RUNX1, TP53 and ASXL1. Enrichment analysis revealed that TRIM6 expression was associated with the PI3K\/AKT signaling pathway and immune response. In addition, in vivo and in vitro experiments further demonstrated that TRIM6 expression could inhibit AML progression via PI3K\/AKT.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusion<\/jats:title>\n<jats:p>TRIM6 is expressed at low levels in AML, correlates with immune infiltration, and may affect AML progression through the PI3K\/AKT signaling pathway.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0329560","type":"journal-article","created":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T17:38:04Z","timestamp":1758130684000},"page":"e0329560","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["TRIM6 affects the prognosis of acute myeloid leukemia through the PI3K\/AKT signaling pathway and is associated with immune infiltration"],"prefix":"10.1371","volume":"20","author":[{"given":"Jingxin","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wu","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuancheng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chenglong","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siqi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianxia","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-5210-5385","authenticated-orcid":true,"given":"Sixi","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2025,9,17]]},"reference":[{"issue":"2","key":"pone.0329560.ref001","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41408-021-00425-3","article-title":"Acute myeloid leukemia: current progress and future directions","volume":"11","author":"H Kantarjian","year":"2021","journal-title":"Blood Cancer J"},{"key":"pone.0329560.ref002","doi-asserted-by":"crossref","first-page":"978786","DOI":"10.3389\/fcell.2022.978786","article-title":"The prognostic marker FLVCR2 associated with tumor progression and immune infiltration for acute myeloid leukemia","volume":"10","author":"X Su","year":"2022","journal-title":"Front Cell Dev Biol"},{"issue":"4","key":"pone.0329560.ref003","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.3390\/ijms22041944","article-title":"Emerging immunotherapy for acute myeloid leukemia","volume":"22","author":"R Tabata","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"26","key":"pone.0329560.ref004","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1182\/blood.2023019961","article-title":"Escape from T-cell-targeting immunotherapies in acute myeloid leukemia","volume":"143","author":"J Vadakekolathu","year":"2024","journal-title":"Blood"},{"issue":"1","key":"pone.0329560.ref005","doi-asserted-by":"crossref","first-page":"166268","DOI":"10.1016\/j.bbadis.2021.166268","article-title":"GPX1-associated prognostic signature predicts poor survival in patients with acute myeloid leukemia and involves in immunosuppression","volume":"1868","author":"J Zhang","year":"2022","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"pone.0329560.ref006","doi-asserted-by":"crossref","first-page":"109729","DOI":"10.1016\/j.vetmic.2023.109729","article-title":"TRIM7 inhibits encephalomyocarditis virus replication by activating interferon-\u03b2 signaling pathway","volume":"281","author":"M Li","year":"2023","journal-title":"Vet Microbiol"},{"issue":"1","key":"pone.0329560.ref007","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s11658-023-00528-8","article-title":"Multipronged regulation of autophagy and apoptosis: emerging role of TRIM proteins","volume":"29","author":"N Ahsan","year":"2024","journal-title":"Cell Mol Biol Lett"},{"issue":"16","key":"pone.0329560.ref008","doi-asserted-by":"crossref","first-page":"12589","DOI":"10.3390\/ijms241612589","article-title":"TRIM14 overexpression induces chemoresistance and malignant behaviors of hepatocellular carcinoma cells by activating the STAT3\/HIF-1\u03b1 pathway","volume":"24","author":"W Xu","year":"2023","journal-title":"Int J Mol Sci"},{"key":"pone.0329560.ref009","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.semcdb.2020.09.013","article-title":"Substrate recognition by TRIM and TRIM-like proteins in innate immunity","volume":"111","author":"H-T Wang","year":"2021","journal-title":"Semin Cell Dev Biol"},{"key":"pone.0329560.ref010","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1515\/med-2021-0003","article-title":"TRIM25 contributes to the malignancy of acute myeloid leukemia and is negatively regulated by microRNA-137","volume":"16","author":"S Wang","year":"2021","journal-title":"Open Med"},{"key":"pone.0329560.ref011","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20194334","article-title":"TRIM31 promotes acute myeloid leukemia progression and sensitivity to daunorubicin through the Wnt\/\u03b2-catenin signaling","volume":"40","author":"Y Xiao","year":"2020","journal-title":"Biosci Rep"},{"issue":"11","key":"pone.0329560.ref012","doi-asserted-by":"crossref","first-page":"3536","DOI":"10.18632\/aging.101995","article-title":"E3-ubiquitin ligase TRIM6 aggravates myocardial ischemia\/reperfusion injury via promoting STAT1-dependent cardiomyocyte apoptosis","volume":"11","author":"G Zeng","year":"2019","journal-title":"Aging (Albany NY)"},{"key":"pone.0329560.ref013","article-title":"TRIM6 interacts with c-Myc and maintains pluripotency of mouse embryonal stem cells","author":"T Sato","year":"2012","journal-title":"J Cell Sci"},{"key":"pone.0329560.ref014","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00833-17","article-title":"The host E3-ubiquitin ligase TRIM6 ubiquitinates the ebola virus VP35 protein and promotes virus replication","volume":"91","author":"P Bharaj","year":"2017","journal-title":"J Virol"},{"issue":"3","key":"pone.0329560.ref015","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.29531","article-title":"TRIM6 facilitates SARS-CoV-2 proliferation by catalyzing the K29-typed ubiquitination of NP to enhance the ability to bind viral genomes","volume":"96","author":"J Zhou","year":"2024","journal-title":"J Med Virol"},{"key":"pone.0329560.ref016","doi-asserted-by":"crossref","first-page":"101999","DOI":"10.1016\/j.tranon.2024.101999","article-title":"TRIM6 promotes glioma malignant progression by enhancing FOXO3A ubiquitination and degradation","volume":"46","author":"J Guo","year":"2024","journal-title":"Transl Oncol"},{"key":"pone.0329560.ref017","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.2147\/IJGM.S341018","article-title":"Identification prognostic value and correlation with tumor-infiltrating immune cells of tripartite-motif family genes in hepatocellular carcinoma","volume":"15","author":"H Su","year":"2022","journal-title":"Int J Gen Med"},{"issue":"1","key":"pone.0329560.ref018","doi-asserted-by":"crossref","first-page":"232","DOI":"10.7150\/jca.87733","article-title":"IGFBP5, as a prognostic indicator promotes tumor progression and correlates with immune microenvironment in Glioma","volume":"15","author":"J Lin","year":"2024","journal-title":"J Cancer"},{"issue":"1","key":"pone.0329560.ref019","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1186\/s12859-022-04894-6","article-title":"High expression of cuproptosis-related SLC31A1 gene in relation to unfavorable outcome and deregulated immune cell infiltration in breast cancer: an analysis based on public databases","volume":"23","author":"L Li","year":"2022","journal-title":"BMC Bioinformatics"},{"issue":"3","key":"pone.0329560.ref020","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1021\/acs.jcim.3c01473","article-title":"Metabolic-related gene prognostic index for predicting prognosis, immunotherapy response, and candidate drugs in ovarian cancer","volume":"64","author":"S Guo","year":"2024","journal-title":"J Chem Inf Model"},{"key":"pone.0329560.ref021","doi-asserted-by":"crossref","first-page":"670490","DOI":"10.3389\/fonc.2021.670490","article-title":"Potential impact of ALKBH5 and YTHDF1 on tumor immunity in colon adenocarcinoma","volume":"11","author":"G Yan","year":"2021","journal-title":"Front Oncol"},{"issue":"5","key":"pone.0329560.ref022","doi-asserted-by":"crossref","first-page":"2866","DOI":"10.1111\/jcmm.14856","article-title":"STAT1 and its related molecules as potential biomarkers in Mycobacterium tuberculosis infection","volume":"24","author":"X-H Yi","year":"2020","journal-title":"J Cell Mol Med"},{"issue":"12","key":"pone.0329560.ref023","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"H D\u00f6hner","year":"2022","journal-title":"Blood"},{"issue":"4","key":"pone.0329560.ref024","doi-asserted-by":"crossref","first-page":"161","DOI":"10.3892\/etm.2024.12449","article-title":"Paclitaxel mediates the PI3K\/AKT\/mTOR pathway to reduce proliferation of FLT3\u2011ITD+ AML cells and promote apoptosis","volume":"27","author":"Y Su","year":"2024","journal-title":"Exp Ther Med"},{"issue":"24","key":"pone.0329560.ref025","doi-asserted-by":"crossref","first-page":"21795","DOI":"10.1021\/acs.jmedchem.4c01354","article-title":"Erlotinib-Gold(I) complex induces leukemia cell DC differentiation and remodels the immunosuppressive microenvironment","volume":"67","author":"X Yu","year":"2024","journal-title":"J Med Chem"},{"issue":"1","key":"pone.0329560.ref026","doi-asserted-by":"crossref","first-page":"19477","DOI":"10.1038\/s41598-023-46521-1","article-title":"ADORA2A promotes proliferation and inhibits apoptosis through PI3K\/AKT pathway activation in colorectal carcinoma","volume":"13","author":"L Ran","year":"2023","journal-title":"Sci Rep"},{"key":"pone.0329560.ref027","doi-asserted-by":"crossref","first-page":"154010","DOI":"10.1016\/j.prp.2022.154010","article-title":"PI3K\/Akt\/mTOR signaling pathway in cancer stem cells","volume":"237","author":"M Karami Fath","year":"2022","journal-title":"Pathol Res Pract"},{"issue":"1","key":"pone.0329560.ref028","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s40364-023-00501-9","article-title":"Biomarkers as targets for CAR-T\/NK cell therapy in AML","volume":"11","author":"R Shao","year":"2023","journal-title":"Biomark Res"},{"issue":"1","key":"pone.0329560.ref029","first-page":"3214","article-title":"Tripartite motif-containing protein 6 facilitates growth and migration of breast cancer through degradation of STUB1","volume":"65","author":"C Wei","year":"2021","journal-title":"Eur J Histochem"},{"issue":"1","key":"pone.0329560.ref030","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s13046-019-1504-5","article-title":"TRIM6 promotes colorectal cancer cells proliferation and response to thiostrepton by TIS21\/FoxM1","volume":"39","author":"S Zheng","year":"2020","journal-title":"J Exp Clin Cancer Res"},{"key":"pone.0329560.ref031","doi-asserted-by":"crossref","first-page":"101999","DOI":"10.1016\/j.tranon.2024.101999","article-title":"TRIM6 promotes glioma malignant progression by enhancing FOXO3A ubiquitination and degradation","volume":"46","author":"J Guo","year":"2024","journal-title":"Transl Oncol"},{"issue":"4","key":"pone.0329560.ref032","doi-asserted-by":"crossref","first-page":"561","DOI":"10.3233\/CBM-181744","article-title":"The diagnostic effect of serum miR-139-5p as an indicator in osteosarcoma","volume":"23","author":"L Zhou","year":"2018","journal-title":"Cancer Biomark"},{"issue":"1","key":"pone.0329560.ref033","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s12883-018-1139-8","article-title":"Targeting the Notch1 oncogene by miR-139-5p inhibits glioma metastasis and epithelial-mesenchymal transition (EMT)","volume":"18","author":"J Li","year":"2018","journal-title":"BMC Neurol"},{"key":"pone.0329560.ref034","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1111\/cas.13002","article-title":"Dual tumor-suppressors miR-139-5p and miR-139-3p targeting matrix metalloprotease 11 in bladder cancer","volume":"107","author":"M Yonemori","year":"2016","journal-title":"Cancer Sci"},{"issue":"3","key":"pone.0329560.ref035","first-page":"1247","article-title":"Decreased expression of miR\u2011490\u20113p in colorectal cancer predicts poor prognosis and promotes cell proliferation and invasion by targeting RAB14","volume":"53","author":"B Wang","year":"2018","journal-title":"Int J Oncol"},{"key":"pone.0329560.ref036","doi-asserted-by":"crossref","first-page":"1343523","DOI":"10.3389\/fmolb.2024.1343523","article-title":"Dynamic interactions in the tumor niche: how the cross-talk between CAFs and the tumor microenvironment impacts resistance to therapy","volume":"11","author":"O Piwocka","year":"2024","journal-title":"Front Mol Biosci"},{"issue":"3","key":"pone.0329560.ref037","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.ccell.2023.02.016","article-title":"The evolving tumor microenvironment: from cancer initiation to metastatic outgrowth","volume":"41","author":"KE de Visser","year":"2023","journal-title":"Cancer Cell"},{"issue":"12","key":"pone.0329560.ref038","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-004794","article-title":"TIGIT blockade repolarizes AML-associated TIGIT+ M2 macrophages to an M1 phenotype and increases CD47-mediated phagocytosis","volume":"10","author":"F Brauneck","year":"2022","journal-title":"J Immunother Cancer"},{"key":"pone.0329560.ref039","article-title":"Targeting macrophages in hematological malignancies: recent advances and future directions","volume":"15","author":"W Li","year":"2022","journal-title":"J Hematol Oncol"},{"key":"pone.0329560.ref040","doi-asserted-by":"crossref","DOI":"10.1186\/s12964-023-01282-2","article-title":"The role of bone marrow microenvironment (BMM) cells in acute myeloid leukemia (AML) progression: immune checkpoints, metabolic checkpoints, and signaling pathways","volume":"21","author":"M Bakhtiyari","year":"2023","journal-title":"Cell Commun Signal"},{"key":"pone.0329560.ref041","doi-asserted-by":"crossref","first-page":"1426474","DOI":"10.3389\/fimmu.2024.1426474","article-title":"Multi-omics analysis and experimental validation of the value of monocyte-associated features in prostate cancer prognosis and immunotherapy","volume":"15","author":"Y Wang","year":"2024","journal-title":"Front Immunol"},{"key":"pone.0329560.ref042","article-title":"Identification and validation of a metabolism-related prognostic signature associated with M2 macrophage infiltration in gastric cancer","volume":"24","author":"Y Liu","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"12","key":"pone.0329560.ref043","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1007\/s12032-022-01856-z","article-title":"Myricetin-induced apoptosis in triple-negative breast cancer cells through inhibition of the PI3K\/Akt\/mTOR pathway","volume":"39","author":"P Sharma","year":"2022","journal-title":"Med Oncol"},{"issue":"3","key":"pone.0329560.ref044","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1158\/1078-0432.CCR-21-1943","article-title":"Activation of PI3K\/AKT pathway is a potential mechanism of treatment resistance in small cell lung cancer","volume":"28","author":"Y Jin","year":"2022","journal-title":"Clin Cancer Res"},{"key":"pone.0329560.ref045","doi-asserted-by":"crossref","first-page":"114084","DOI":"10.1016\/j.biopha.2022.114084","article-title":"New light on treatment of cervical cancer: Chinese medicine monomers can be effective for cervical cancer by inhibiting the PI3K\/Akt signaling pathway","volume":"157","author":"F Liu","year":"2023","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"pone.0329560.ref046","doi-asserted-by":"crossref","first-page":"119607","DOI":"10.1016\/j.bbamcr.2023.119607","article-title":"Regulatory role of RBM39 in acute myeloid leukemia: mediation through the PI3K\/AKT pathway","volume":"1871","author":"X Zhang","year":"2024","journal-title":"Biochim Biophys Acta Mol Cell Res"},{"key":"pone.0329560.ref047","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.3109\/07357900902769749","article-title":"Cell adhesion molecules: role and clinical significance in cancer","volume":"27","author":"N Makrilia","year":"2009","journal-title":"Cancer Invest"},{"issue":"12","key":"pone.0329560.ref048","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.3390\/biom11121850","article-title":"CD44: a multifunctional mediator of cancer progression","volume":"11","author":"M Hassn Mesrati","year":"2021","journal-title":"Biomolecules"},{"key":"pone.0329560.ref049","doi-asserted-by":"crossref","first-page":"8043","DOI":"10.1523\/JNEUROSCI.1401-23.2023","article-title":"Glial cell adhesion molecule (GlialCAM) determines proliferative versus invasive cell states in glioblastoma","volume":"43","author":"A De","year":"2023","journal-title":"J Neurosci"},{"key":"pone.0329560.ref050","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.cytogfr.2021.07.001","article-title":"ALCAM\/CD166: a pleiotropic mediator of cell adhesion, stemness and cancer progression","volume":"61","author":"F Ferragut","year":"2021","journal-title":"Cytokine Growth Factor Rev"},{"key":"pone.0329560.ref051","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22189804","article-title":"Chemokine-directed tumor microenvironment modulation in cancer immunotherapy","volume":"22","author":"P Bule","year":"2021","journal-title":"Int J Mol Sci"},{"key":"pone.0329560.ref052","doi-asserted-by":"crossref","first-page":"1224269","DOI":"10.3389\/fimmu.2023.1224269","article-title":"Factors impacting the benefits and pathogenicity of Th17 cells in the tumor microenvironment","volume":"14","author":"J Xing","year":"2023","journal-title":"Front Immunol"},{"issue":"1","key":"pone.0329560.ref053","doi-asserted-by":"crossref","first-page":"20220538","DOI":"10.1515\/biol-2022-0538","article-title":"PI3K\/AKT\/mTOR pathway and its related molecules participate in PROK1 silence-induced anti-tumor effects on pancreatic cancer","volume":"18","author":"F Wang","year":"2023","journal-title":"Open Life Sci"},{"key":"pone.0329560.ref054","article-title":"STIL promotes tumorigenesis of bladder cancer by activating PI3K\/AKT\/mTOR signaling pathway and targeting C-Myc","volume":"14","author":"H Yu","year":"2022","journal-title":"Cancers"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0329560","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T17:38:14Z","timestamp":1758130694000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0329560"}},"subtitle":[],"editor":[{"given":"Francesco","family":"Bertolini,","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2025,9,17]]},"references-count":54,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,9,17]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0329560","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,17]]}}}